+1 (713) 400-6400
3200 Southwest Fwy #2240 Phoenix TowerHouston, TX 77027
© 2020 Marker Therapeutics, Inc.
The U.S. Department of Defense (DoD) has awarded Mayo Clinic researchers $11 million to conduct a Phase 2 trial investigating the TPIV110 vaccine, in combination with Herceptin (trastuzumab), as a therapy for women with HER2-positive breast cancer.
Get Marker News Delivered To Your Inbox